#Pharma & #Cannabis Stocks See Opportunities in
Europe: (OTCQB: $INNV) (ASX: OCC) (NASDAQ: $PCRX) (TSXV: $HVT.V) (OTCQX:
$HRVOF)
Muscle and Repair Treatments versus Surgery and how
Europe and Global Markets offer New Opportunities
Point Roberts, WA and Delta, BC - June 12, 2019
(Investorideas.com Newswire) Investorideas.com, a leading investor news
resource covering biotechnology and pharmaceutical stocks releases a sector
snapshot reporting on the ongoing growth of OTC pain medication due to consumer
demand and a move away from traditional surgeries. More companies are taking a
global approach and are seeking to gain approval not only in the US, but also
European markets moving forward.
According to a market research report published by P&S Intelligence, the chronic pain treatment market is “expected to reach $105.9 billion by
2024. The market growth is primarily driven by the rising prevalence of chronic
conditions, surging geriatric population, and increasing government support
toward chronic pain management.”
MotleyFool recently discussed the key differences
between the United States and European drug markets, specifically focusing on
the key differences in drug approval. “The United States and Europe are
drugmakers' biggest markets, but just because a drug wins approval in one
doesn't mean it will get the nod in the other. Each market has its own system
for clinical trials and drug reviews, and there are key differences in
commercializing drugs in these regions that investors ought to know about
before investing.”
Looking to European
markets, Innovus Pharmaceuticals, Inc.
(OTCQB: INNV), an emerging commercial-stage
pharmaceutical company that delivers safe, innovative and effective
over-the-counter medicine and consumer care products to improve men’s and
women's health and respiratory diseases, recently announced that it has received the CPNP notification
number required to commercialize CarvaNum®, its product for muscle recovery, in
all 28 member countries of the European Union. This represents the fifth
Innovus Pharma product to receive CPNP notification in the European Union so
far, the others being Zestra®, Zestra Glide®, Sensum+®, and Diabasens®. The
product will be available as an over the counter (“OTC”) or behind the counter
product and does not require a prescription.
Read this in full at https://www.investorideas.com/news/2019/biotech/06121PharmaCannabis-Europe.asp
“We are pleased to announce
the receipt of the CPNP in the European Union for CarvaNum®. CarvaNum®’s market
for muscle recovery is fairly large in the EU and we look forward to growing it
along with our other products in that region,” said Innovus Pharma CEO, Dr.
Bassam Damaj.
“We will continue to
file for approval for other products in the European Union, as we expect to
grow our approved and/or notified product portfolio there in 2019 to also
include Vesele®, UriVarx®, Prostagorx®, ArthriVarx®, Trexar® and BH
Testosterone®.”
Innovus is also
working on filing for CarvaNum® as a homeopathic drug for muscle cramps in the
US and Canada.
Orthocell Limited (ASX: OCC) recently provided its first batch of evidence supporting the
efficacy of its CelGro™ nerve regeneration platform.
The company published
results on the first four patients to complete the clinical trial using
CelGro™, with patients experiencing an 83% improvement in muscle power.
Orthocell said it
conducted the trial to demonstrate the effectiveness of CelGro™ and confirm
that the platform can be used to guide and promote “tensionless nerve
regeneration in damaged peripheral nerves of the hand and upper limb.”
If successfully
proven, Orthocell plans to market its CelGro™ platform in Europe and other
major markets globally. In the US alone, over 20 million people suffer from
peripheral nerve injury as a result of acute muscle injuries every year, at an
annual cost of approximately US$150 billion (A$213 billion).
Pacira BioSciences, Inc. (NASDAQ: PCRX) recently announced the publication of its multinational Phase 3 study
supporting the efficacy and safety of EXPAREL® (bupivacaine liposome injectable
suspension) as a single-injection interscalene brachial plexus nerve block
(ISNB) in patients undergoing total shoulder arthroplasty or rotator cuff
repair. The results demonstrate that EXPAREL® significantly improved pain
control and reduced opioid consumption through 48 hours compared with placebo
and a standardized pain management protocol alone. The data, which provided the
basis for FDA approval for this indication, was published in Pain Medicine.
“Traditionally,
clinicians seeking regional pain control have been forced to choose between
single-injection blocks with a duration of efficacy that does not match
analgesic requirements or continuous blocks that are long-lasting but hinder
patient mobility due to cumbersome catheters and pumps. Results from this study
illustrate the clinical effectiveness of interscalene brachial plexus nerve
block with EXPAREL®, which provides prolonged pain control in a single dose without
the need for additional equipment,” said Manish Patel, orthopedic surgeon at
Eastern Virginia Medical School in Franklin, VA who was also a study
investigator and is lead author on the publication. “Further, robust pain
control coupled with a reduction or total elimination of opioid requirements,
as EXPAREL® demonstrated in this study, are two critical factors toward the
increasing clinical goal of moving inpatient procedures to an outpatient
setting.”
This uptrend in pain
management treatment is also attracting outside interest from the Cannabis
sector as Harvest One Cannabis Inc (TSXV;HVT) (OTCQX:HRVOF) recently announced that it has entered into a definitive
agreement to acquire Delivra Corp. for C$19 million, in a stock deal to
strengthen its medical and wellness division.
Harvest One's
acquisition of Delivra furthers the company's health, wellness, and self-care
strategy by adding LivRelief™ to its medical and wellness portfolio. Delivra’s
LivRelief™ brand produces a variety of topicals and creams with existing
distribution channels across Canada. This will well position Harvest One for
the time when cannabis-infused products are legalized in Canada, around Fall of
2019.
"The acquisition
of Delivra by Harvest One puts further emphasis on the Harvest One goal of
being a leading house of brands in the global health, wellness, and self-care
sector,” said Harvest One CEO, Grant Froese. “The addition of LivRelief™, which
is already on retail shelves across Canada, will give Harvest One a head start
for cannabis-infused products in Canada.”
Though many tend to look at the US as the
largest market in dollar terms, the European market is still significant with
more than 741 million people living there, a fact many of these OTC pain
medication companies are taking into consideration when looking to maximize
exposure and company revenues moving forward. OTC pain medication is showing
impressive gains, but this is a global market moving forward and the companies
who gain approval in both markets are hoping to gain a competitive advantage.
Visit the Investorideas.com biotech and
pharma stock directory at Investorideas.com
About Investorideas.com - News that Inspires
Big Investing Ideas
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Disclosure: this article
featuring INNV is a paid for service on Investorideas.com ( two thousand ) by a
third party. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment